Our platform approach allows shareholders to benefit from the revenues of multiple holdings and subsidiaries. We envision a future where "farmaceutical" products will usher in a new period of health and wellness based on psychoactive compounds and clean label products.
Cybin Inc reports its fiscal Q2 results for 2021. Advanced several drug development candidates and received a Schedule I manufacturing license. Cash and equivalents of CAD$75.2 million as of September 30, 2021.